ArticleInternational journal of endocrinology2026
A Novel Sarcopenia Screening Score Based on Thyroid Function Parameters in Euthyroid Middle-Aged and Elderly Chinese Adults.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This research aims to develop an alternative sarcopenia screening score based on thyroid hormone function parameters, intended for screening and validating the probability of having sarcopenia among middle-aged and elderly participants with normal thyroid function tests in China. Methods: This multicenter, cross-sectional study assessed the prevalence of sarcopenia among 3,858 thyroid-healthy Chinese adults across hospitals in western China hospitals. Participants were randomized to exploratory and validation cohorts. After applying Lasso to select variables, multivariate logistic regression analysis was conducted. We developed a novel sarcopenia screening score from exploratory data, subsequently validating it internally across both cohorts. Results: The new sarcopenia screening score comprises five variables: age, body mass index (BMI), calf circumference (CC), aspartate aminotransferase/alanine aminotransferase ratio (AST/ALT), and free T4 (FT4), with a scoring range of 0-14. The area under the receiver operating characteristic (ROC) curve for screening for sarcopenia was 0.845 (95% CI: 0.831-0.859) in the exploratory group and 0.854 (95% CI: 0.831-0.874) in the validation group. At the optimal cutoff of 3, the sensitivity and specificity were 78.3% and 75.1%, respectively, in the exploratory cohort; in the validation cohort, with a cutoff of 4, sensitivity and specificity were 68.4% and 87.0%. The Brier score was 0.092 in the exploratory cohort and 0.068 in the validation cohort, confirming satisfactory calibration. Conclusion: The newly developed sarcopenia screening score shows promise as a practical tool for identifying sarcopenia in middle-aged and elderly participants with normal thyroid function tests in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.